Allogene May Have Cracked The Off-The-Shelf CAR-T Problem

42% Complete Response At Six Months Matches Auto-CAR-Ts

Allogeneic candidate’s durability is holding up thanks to a novel conditioning regimen, but Phase II data will be crucial test.

Allogene building

Allogene has taken a step closer to developing a viable off-the-shelf CAR-T therapy, becoming the first to match the durability of established autologous treatments after many years of setbacks and disappointments.

Its updated Phase I data presented at the American Society of Clinical Oncology congress show a complete response rate of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip